HRMY vs INSM
HRMY: Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor antagonist for narcolepsy, with an expanding pipeline in rare epilepsy and sleep disorders. INSM: A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in respiratory, immunology, and neurological rare diseases.
Side-by-side fundamentals
| Metric | HRMY | INSM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $34.86 | $106.64 | |
| Market cap as of 2026-07-23 | $2.0B | $23.4B | |
| P/E as of 2026-07-23 | 13.86 | n/a | |
| PEG as of 2026-07-23 | 0.20 | n/a | |
| Net margin as of 2026-07-23 | +16.2% | -144.4% | HRMY higher |
| Gross margin as of 2026-07-23 | +76.5% | +81.8% | INSM higher |
| Operating margin as of 2026-07-23 | +21.1% | -140.6% | HRMY higher |
| ROE as of 2026-07-23 | +17.2% | -130.1% | HRMY higher |
| ROA as of 2026-07-23 | +12.0% | -51.6% | HRMY higher |
| Debt / equity as of 2026-07-23 | 0.17 | 1.03 | HRMY lower |
| Revenue growth (YoY) as of 2026-07-23 | +20.7% | +115.1% | INSM higher |
| Revenue CAGR (3y) SEC XBRL | +25.6% | +35.2% | INSM higher |
| Beta as of 2026-07-23 | 0.91 | 0.80 | |
| 1-year return as of 2026-07-22 close | +4.5% | +5.7% | INSM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.